{"id":"NCT00601367","sponsor":"Sprout Pharmaceuticals, Inc","briefTitle":"Flibanserin Evaluation Over 28 Additional Weeks in Hypoactive Sexual Desire Disorder","officialTitle":"A Twenty-Eight Week, Open-Label, Safety Study of Flibanserin 50 Mgs to 100 Mgs Daily in Premenopausal European Women With HSDD","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2008-01","primaryCompletion":"2009-10","completion":"2009-10","firstPosted":"2008-01-28","resultsPosted":"2014-06-20","lastUpdate":"2014-06-20"},"enrollment":480,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Sexual Dysfunctions, Psychological"],"interventions":[{"type":"DRUG","name":"flibanserin flexible dose","otherNames":[]}],"arms":[{"label":"flibanserin flexible dose","type":"EXPERIMENTAL"}],"summary":"Safety profile of flibanserin over 28 additional weeks Distribution of preferred dose regimens","primaryOutcome":{"measure":"Frequency of Adverse Events","timeFrame":"28 weeks","effectByArm":[{"arm":"Flibanserin Flexible Dose","deltaMin":331,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"FEMALE","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":5},"locations":{"siteCount":68,"countries":["Austria","Belgium","Czechia","Finland","France","Germany","Hungary","Italy","Netherlands","Spain","Sweden","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":480},"commonTop":["Fatigue","Headache","Nasopharyngitis","Nausea","Dizziness"]}}